CG Oncology Q2 net loss $79.1M ($0.90/shr); adds $500M ATM capacity

CG Oncology, Inc.

Net loss of $79.1M ($0.90 per share) vs $41.4M ($0.54) in Q2 2025; R&D $54.7M, G&A $29.0M.
Cash, equivalents and marketable securities $1.0B as of June 30, 2026, down from $1.1B on March 31, 2026.
Filed Amendment No. 2 to Prospectus to increase ATM shares by $500M (previously sold ~$550M).
PIVOT-006 Phase 3 topline data for cretostimogene in intermediate-risk NMIBC expected near-term.
BLA submission for HR BCG-unresponsive NMIBC with CIS expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.